Key statistics
On Friday, Hansa Biopharma AB (0RC7:LSE) closed at 33.72, -21.51% below its 52-week high of 42.96, set on Oct 01, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 33.33 |
|---|---|
| High | 33.72 |
| Low | 33.72 |
| Bid | -- |
| Offer | -- |
| Previous close | 33.31 |
| Average volume | 4.72k |
|---|---|
| Shares outstanding | 101.76m |
| Free float | 48.58m |
| P/E (TTM) | -- |
| Market cap | 3.44bn SEK |
| EPS (TTM) | -6.44 SEK |
Data delayed at least 20 minutes, as of Feb 27 2026 17:18 GMT.
More ▼
Press releases
- Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
- Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
More ▼
